NeuPSIG:investing in solutions to the growing global challenge of neuropathic pain by Smith, Blair & Raja, Srinivasa N.
                                                              
University of Dundee
NeuPSIG
Smith, Blair; Raja, Srinivasa N.
Published in:
BRITISH JOURNAL OF ANAESTHESIA
DOI:
10.1093/bja/aex276
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Smith, B., & Raja, S. N. (2017). NeuPSIG: investing in solutions to the growing global challenge of neuropathic
pain. BRITISH JOURNAL OF ANAESTHESIA, 119(4), 705-708. https://doi.org/10.1093/bja/aex276
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 05. Apr. 2019
For Peer Review
 
 
 
 
 
 
NeuPSIG: Investing in solutions to the growing global 
challenge of neuropathic pain 
 
 
Journal: British Journal of Anaesthesia 
Manuscript ID Draft 
Manuscript Type: Editorial 
Date Submitted by the Author: n/a 
Complete List of Authors: Smith, Blair; University of Dundee, Division of 
Population Health Sciences 
Raja, Srinivasa N; Johns Hopkins Hospital and Health 
System, Division of Pain Medicine, Department of 
Anesthesiology and Critical Care Medicine 
<a 
href=https://www.nlm.nih.gov/mesh/MBrowser.html 
target=_new>Mesh keywords</a>: 
Neuropathic pain, Cancer-related pain 
  
 
 
British Journal of Anaesthesia
For Peer Review
NeuPSIG: Investing in solutions to the growing global challenge of neuropathic pain 
Blair H. Smith
a 
Srinivasa N. Raja
b 
a = Division of Population Health Sciences University of, Dundee, Scotland, UK 
b = Johns Hopkins University School of Medicine, Baltimore, USA 
 
 
 
Corresponding author: 
Professor Blair H. Smith 
Division of Population Health Sciences, University of Dundee 
Mackenzie Building, Kirsty Semple Way 
Ninewells Hospital & Medical School 
DUNDEE DD2 4DB 
Scotland, UK 
 
Phone    +44 (0)1382 383728 
Email       b.h.smith @dundee.ac.uk 
This manuscript is submitted as an Editorial. 
 
 
This work is supported in part by a NIH grant, NS26363 (SNR). 
Running title – The global challenge of neuropathic pain 
  
Page 1 of 8 British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Abstract 
Neuropathic pain is a common and distressing condition, for which treatment is often unsatisfactory.  
NeuPSIG, the Special Interest Group on Neuropathic Pain, is part of the International Association for 
the Study of Pain, and has been working hard to improve understanding and management of 
neuropathic pain since 1999.  Chronic cancer-related pain arises through many different, often 
concurrent mechanisms, is often neuropathic, and affects the lives of a growing number of cancer 
survivors.  Cancer-related pain was a focus of part of NeuPSIG’s 6
th
 International Congress on 
Neuropathic Pain.  Two comprehensive reviews, arising from this Congress and published in this 
edition of the Journal, present state of the art appraisals of current knowledge of (1) pain in cancer 
survivors; and (2) chemotherapy-induced peripheral neuropathy.   
Introduction 
This issue of the Journal includes two excellent review papers discussing epidemiology, mechanisms 
and management of pain after cancer.
1, 2  
These were presented in a workshop at the 6
th
 
International Congress on Neuropathic Pain, in June 2017, sponsored by the British Journal of 
Anaesthesia (BJA).  Cancer pain is a distressing, chronic painful condition, which is generally under-
recognized yet whose importance in society is increasing as cancer survivorship improves and people 
live longer with lasting side effects of treatment.
3
 
In a wide-ranging and comprehensive review, Brown and Farquhar-Smith examine pain in cancer 
survivors, explaining the multifarious, often concurrent causes of pain to which this growing 
population is vulnerable.
1
 In an additional detailed review, Flatters and colleagues focus on 
chemotherapy induced peripheral neuropathy (CIPN) that in some cases may be severe enough to 
present as a barrier to the optimal treatment with chemotherapeutic agents and is one of the most 
distressing conditions in cancer survivors.
2
    These two reports on pain associated with cancer and 
its treatment highlight the emergence of novel clinical challenges as a sequel of therapeutic 
advances in the management of patients with cancer.  The authors present state of the art reviews 
that include findings from the forefront of research on this important topic, from the bench to the 
bedside and beyond.   
Neuropathic pain 
Chronic painful conditions, such as cancer pain, cause, by far, the most disability globally and in 
every individual country.
4, 5
  Although prevalence varies between countries and regions, large 
epidemiological studies found that approximately 20-30% of European adults have significant 
chronic pain, and that it is often managed unsatisfactorily.
6, 7
  Its most successful management 
requires multi-disciplinary approaches including pharmacological, non-pharmacological and self-
management techniques.  
The International Association for the Study of Pain (IASP) exists to bring together scientists, 
clinicians, health-care providers, and policymakers to stimulate and support the study of pain and 
translate that knowledge into improved pain relief worldwide.
8
  It includes 20 Special Interest 
Groups (SIGs), the largest of which is that for neuropathic pain (NeuPSIG).  NeuPSIG’s aim is to 
advance the understanding of mechanisms, assessment, prevention, and treatment of neuropathic 
pain.
9
   
Neuropathic pain (NP) is pain caused by a lesion or disease affecting the somatosensory system.
10, 11
  
It is typified by positive and negative symptoms such paraesthesia, altered sensation and a shooting 
or crawling nature of the pain, and signs such as sensory deficits, allodynia, hyperalgesia and an 
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altered appearance of the skin over the affected area.  Common causes of peripheral NP include 
diabetic neuropathy, postherpetic neuralgia and lumbar radicular neuropathy.  Central NP can arise 
in association with strokes, multiple sclerosis and other neurological and metabolic conditions.  In 
cancer, NP may be the result of surgery, chemotherapy and/or radiotherapy, as well as through 
other treatments or specific disease mechanisms.
1
  Pain with neuropathic features is more prevalent 
than generally realized, with population-based studies finding that 7-10% of adults are affected.
12
  
NP is more distressing than nociceptive pain, with a greater impact on life and health,
13
 and the 
impact is more dependent on its severity than its underlying cause.
14, 15
  In one study, 17% of people 
with NP classified its impact on quality of life as “worse than death”, using well validated 
instruments.
16
   
Unlike nociceptive pain, NP responds poorly to many of the standard analgesics, such as non-
steroidal anti-inflammatory drugs.
17
  Early diagnosis is therefore important, in order that treatment 
with more effective first-line medications, such as a tricyclic anti-depressant, a gabapentinoid, or a 
serotonin-norepinephrine reuptake inhibitor may be prescribed.  However, even the most effective 
medicines have a number needed to treat of around 4 to 8 in order to achieve 50% reduction in pain 
relief, and often cause unacceptable side effects.  Response to treatment seems to be less 
dependent on the underlying cause than on specific pain mechanisms,
18
 and it is increasingly 
recognized that phenotyping and stratification according to factors such as sensory profiling
 19
 and 
endogenous pain modulation measures
20
 might allow a precision approach to treatment selection.  
However, these techniques are a long way from the standard clinic, and it is important that research 
into mechanisms and management of this distressing condition is prioritised. 
NeuPSIG 
The Congress at which these papers were presented is NeuPSIG’s biannual flagship.  NeuPSIG 
includes over one thousand members from different scientific and clinical disciplines, and from 75 
countries.  It was formed in 1999 and has achieved much in the fight against NP.  NeuPSIG prides 
itself in taking a rigorous, evidence-based approach to the initiatives to which it attends, and aims 
for products of the highest quality, to be adopted as standard by the international community.  
Examples of such outputs are shown in Box 1.  They include evidence-based recommendations on 
various aspects of the assessment and management of NP, each based on detailed systematic 
reviews and expert interpretation and consensus.  They also include a recent submission to the 
World Health Organization for inclusion of gabapentin in its Model Essential Medicines List – at 
present amitriptyline is the only medicine included for treating neuropathic pain.  Previous NeuPSIG 
work has shown that even this was not always available, and that other effective medicines were of 
limited availability in many countries, particularly in the developing world. 
In addition to these published outputs, NeuPSIG is committed to educating clinicians and the public 
about NP.  It has led or contributed to training programmes in various countries including India, 
South Africa, Indonesia, Malaysia, and Chile.  It has produced instructional videos on the neurological 
examination of central and peripheral NP, and of the cranial nerves.  In 2015, NeuPSIG led IASP’s 
Global Year Against Neuropathic Pain campaign,
21 
which included educational material and events, 
for scientists, clinicians, the press and the public.  Other educational initiatives have included 
satellite symposia to the World Congress on Pain at Santiago, Chile and Yokohama, Japan and special 
supplements to the journal Pain, with updated reviews focused on advances in basic and clinical 
aspects of neuropathic pain. 
NeupSIG 2017 
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But the biannual Congress on Neuropathic Pain is where the front line of research on neuropathic 
pain is on display.  Presentations range from basic science, through translational research and 
clinical trials to applied research in the clinic and the community.  This year’s Congress, the 6
th
, was 
attended by delegates from more than 50 different countries and included papers on: NP regulation 
by astrocytes, microglia and macrophages; emerging cell-based therapy for NP; psychological and 
genetic prediction of the placebo response; and the impact of NP on the global burden of disease.  In 
addition, internationally recognized experts provided plenary overviews of the state of the art in 
important aspects of NP, including genetic research, clinical assessment, new treatments, and 
neuropathic itch.   
NeuPSIG 2017 workshop on cancer-related pain 
The BJA-sponsored workshop on cancer-related pain was exemplary in its range of material, from 
dorsal root ganglion and cellular mechanisms, to trials, treatment and translation.  This work, and its 
dissemination at the Congress and in this Journal, will undoubtedly inform clinical practice and 
further research in this important area. 
A systematic review and meta-analysis of studies examining the epidemiology of cancer pain found 
that about 40% of cancer patients are affected by NP, and that 20% of this is related to cancer 
treatment, rather than the cancer itself.
22
  As Brown and Farquhar-Smith point out, however, this 
relatively small proportion translates to a large and growing population presenting an increasing 
challenge to clinicians and society.
1
  A cancer survivor – someone ‘living with and beyond cancer’
23
 – 
is likely to experience some of a number of lasting physical, psychological and social sequelae.  
Clearly, these will depend on the nature of the disease, its treatment and pre-existing and 
subsequent factors (also physical, psychological and social).  With pain – particularly that of 
neuropathic origin – being one of the most lasting and distressing, it is important that we do our 
best to understand the causes and mechanisms, in order to target treatment and prevention 
effectively.  Brown and Farquhar-Smith list the possible causes: pain from the tumour (including 
neuropathies associated with haematological malignancy); bone pain; post-surgical pain; neuropathy 
induced by chemotherapy, biological agents, monoclonal antibodies or aromatase inhibitors; and 
radiation-induced pain.
1
  They describe the latest knowledge of the biological mechanisms of each of 
these, such as the host of cytokines and growth factors released by the tumour and stromal cells 
that lead to neuronal sensitization, and encourage us by indicating how this knowledge is leading to 
new potential treatments.  Emphasising that a ‘one size fits all’ approach to treating pain in cancer 
survivors is unhelpful, they summarise the treatments available and the evidence for their 
effectiveness.  They conclude that there are sufficient similarities in the approaches to management 
for them to propose the umbrella of ‘chronic cancer-related pain’ (CCRP) to promote investment of 
resources to further understand treatment and prevention. 
Considering one of the main culprits of persistent pain in cancer treatment and survival, Flatters and 
colleagues note that the mechanisms of CIPN are poorly understood, and treatment is often 
unsatisfactory.
2
  The arrival of CIPN often comes as a surprise to patients who have embarked on a 
course of chemotherapy, and its persistence disrupts their life which is increasingly likely to last for 
many years after treatment is complete.  Early assessment is therefore essential, though not 
straightforward, as the variety of tools available for this purpose demonstrates.  Similarly, 
understanding its biological mechanisms and responses to potential treatments are complex, one 
issue being the difficulty of developing ethical animal models that represent persistent CIPN in 
humans accurately.  Nonetheless, the authors summarise important recent advances in 
understanding the roles of mitochondrial dysfunction, oxidative stress, immune cells, and ion 
Page 4 of 8British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
channels in causing CIPN, and the potential new treatments (or new combinations of existing 
treatments) that might reduce the burden of disease. 
Conclusion  
One common theme recurring through both of these reviews
1,
 
2
 is the lack of evidence for 
effectiveness of treatments currently available, and the paucity of clinical research to date on 
possible new treatments.  There are, of course, many reasons for these gaps, including the logistics 
and high costs of randomised controlled trials, difficulty in identifying and recruiting sufficient 
suitable trial participants, and the stage in the development pipeline at which newer drugs currently 
sit.  Similar research gaps are identified for many established treatments available for NP more 
generally, particularly evidence on their long-term effectiveness.
17
  However, there is little doubt 
that one reason is the relative lack of public and professional educational focus on chronic 
(neuropathic and/or cancer-related) pain, surprising and indefensible given the high prevalence and 
resultant disability worldwide.
4
  It is essential that we, as a global society, invest more time, money, 
education and research into improving the understanding, assessment, management and prevention 
of chronic pain; and that a greater proportion of these resources that are currently available for 
cancer is devoted to cancer-related chronic pain.  This is why the BJA sponsored this workshop, and 
is the primary mission of the IASP and NeuPSIG.   
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Box 1.  Examples of NeuPSIG outputs 
• Recommendations on pharmacological treatment of neuropathic pain in adults, first in 
2007
24
 updated in 2010,
25  
and again in 2015
 17
   
 
• Guidance for assessing neuropathic pain in primary care (2009)
26
   
 
• Definition and a grading system for neuropathic pain, first in 2008,
27
 updated in 2016
28
   
 
• Guidelines for the assessment of neuropathic pain (2011)
29
   
 
• Commentary on the need for systematic classification of neuropathic pain to ensure 
appropriate allocation of health care resources and implementation of evidence-based 
guidelines (2013)
30
 
 
• Recommendations for conducting quantitative sensory testing for neuropathic pain in 
clinical practice and research (2013)
27
   
 
• Recommendations on interventional management of neuropathic pain (2013)
31
   
 
• An international consensus on phenotyping neuropathic pain for genetic studies (NeuroPPIC, 
2015)
32
   
 
• Instructional videos on neurological examinations of patients with neuropathic pain
9
 
 
• A proposal to the World Health Organization (WHO) for inclusion of gabapentin in its Model 
List of Essential Medicines as treatment for neuropathic pain (2015)
33,
 
34
 
 
• Definition of neuropathic pain for the WHO’s International Classification of Diseases, 
forthcoming 11
th
 revision (ICD-11)
35,
 
36
   
 
 
Page 8 of 8British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
